Jennifer Kollmer1, Felix Sahm2, Ute Hegenbart2, Jan C Purrucker2, Christoph Kimmich2, Stefan O Schönland2, Ernst Hund2, Sabine Heiland2, John M Hayes2, Arnt V Kristen2, Christoph Röcken2, Mirko Pham2, Martin Bendszus2, Markus Weiler1. 1. From the Department of Neuroradiology (J.K., S.H., M.P., M.B.), Amyloidosis Center Heidelberg (J.K., U.H., J.C.P., C.K., S.O.S., E.H., A.V.K., M.W.), Department of Neuropathology (F.S.), Medical Department V (U.H., C.K., S.O.S.), Department of Neurology (J.C.P., E.H., M.W.), Division of Experimental Radiology (S.H.), Department of Neuroradiology, and Medical Department III (A.V.K.), Heidelberg University Hospital; CCU Neuropathology (F.S.), German Consortium for Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany; Department of Neurology (J.M.H.), University of Michigan, Ann Arbor; Department of Pathology (C.R.), University of Kiel; and Department of Neuroradiology (M.P.), Würzburg University Hospital, Germany. jennifer.kollmer@med.uni-heidelberg.de markus.weiler@med.uni-heidelberg.de. 2. From the Department of Neuroradiology (J.K., S.H., M.P., M.B.), Amyloidosis Center Heidelberg (J.K., U.H., J.C.P., C.K., S.O.S., E.H., A.V.K., M.W.), Department of Neuropathology (F.S.), Medical Department V (U.H., C.K., S.O.S.), Department of Neurology (J.C.P., E.H., M.W.), Division of Experimental Radiology (S.H.), Department of Neuroradiology, and Medical Department III (A.V.K.), Heidelberg University Hospital; CCU Neuropathology (F.S.), German Consortium for Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany; Department of Neurology (J.M.H.), University of Michigan, Ann Arbor; Department of Pathology (C.R.), University of Kiel; and Department of Neuroradiology (M.P.), Würzburg University Hospital, Germany.
Abstract
OBJECTIVE: To detect and quantify lesions of the small-caliber sural nerve (SN) in symptomatic and asymptomatic transthyretin familial amyloid polyneuropathy (TTR-FAP) by high-resolution magnetic resonance neurography (MRN) in correlation with electrophysiologic and histopathologic findings. METHODS: Twenty-five patients with TTR-FAP, 10 asymptomatic carriers of the mutated transthyretin gene (mutTTR), and 35 age- and sex-matched healthy controls were prospectively included in this cross-sectional case-control study. All participants underwent 3T MRN with high-structural resolution (fat-saturated, T2-weighted, and double-echo sequences). Total imaging time was ≈45 minutes per patient. Manual SN segmentation was performed from its origin at the sciatic nerve bifurcation to the lower leg with subsequent evaluation of quantitative microstructural and morphometric parameters. Additional time needed for postprocessing was ≈1.5 hours per participant. Detailed neurologic and electrophysiologic examinations were conducted in the TTR group. RESULTS: T2 signal and proton spin density (ρ) reliably differentiated between TTR-FAP (198.0 ± 13.3, 429.6 ± 15.25), mutTTR carriers (137.0 ± 16.9, p = 0.0009; 354.7 ± 21.64, p = 0.0029), and healthy controls (90.0 ± 3.4, 258.2 ± 9.10; p < 0.0001). Marked differences between mutTTR carriers and controls were found for T2 signal (p = 0.0065) and ρ (p < 0.0001). T2 relaxation time was higher in patients with TTR-FAP only (p = 0.015 vs mutTTR carriers, p = 0.0432 vs controls). SN caliber was higher in patients with TTR-FAP vs controls and in mutTTR carriers vs controls (p < 0.0001). Amyloid deposits were histopathologically detectable in 10 of 14 SN specimens. CONCLUSIONS: SN injury in TTR-FAP is detectable and quantifiable in vivo by MRN even in asymptomatic mutTTR carriers. Differences in SN T2 signal between controls and asymptomatic mutTTR carriers are derived mainly from an increase of ρ, which overcomes typical limitations of established diagnostic methods as a highly sensitive imaging biomarker for early detection of peripheral nerve lesions. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that MRN accurately identifies asymptomatic mutTTR carriers.
OBJECTIVE: To detect and quantify lesions of the small-caliber sural nerve (SN) in symptomatic and asymptomatic transthyretinfamilial amyloid polyneuropathy (TTR-FAP) by high-resolution magnetic resonance neurography (MRN) in correlation with electrophysiologic and histopathologic findings. METHODS: Twenty-five patients with TTR-FAP, 10 asymptomatic carriers of the mutated transthyretin gene (mutTTR), and 35 age- and sex-matched healthy controls were prospectively included in this cross-sectional case-control study. All participants underwent 3T MRN with high-structural resolution (fat-saturated, T2-weighted, and double-echo sequences). Total imaging time was ≈45 minutes per patient. Manual SN segmentation was performed from its origin at the sciatic nerve bifurcation to the lower leg with subsequent evaluation of quantitative microstructural and morphometric parameters. Additional time needed for postprocessing was ≈1.5 hours per participant. Detailed neurologic and electrophysiologic examinations were conducted in the TTR group. RESULTS: T2 signal and proton spin density (ρ) reliably differentiated between TTR-FAP (198.0 ± 13.3, 429.6 ± 15.25), mutTTR carriers (137.0 ± 16.9, p = 0.0009; 354.7 ± 21.64, p = 0.0029), and healthy controls (90.0 ± 3.4, 258.2 ± 9.10; p < 0.0001). Marked differences between mutTTR carriers and controls were found for T2 signal (p = 0.0065) and ρ (p < 0.0001). T2 relaxation time was higher in patients with TTR-FAP only (p = 0.015 vs mutTTR carriers, p = 0.0432 vs controls). SN caliber was higher in patients with TTR-FAP vs controls and in mutTTR carriers vs controls (p < 0.0001). Amyloid deposits were histopathologically detectable in 10 of 14 SN specimens. CONCLUSIONS: SN injury in TTR-FAP is detectable and quantifiable in vivo by MRN even in asymptomatic mutTTR carriers. Differences in SN T2 signal between controls and asymptomatic mutTTR carriers are derived mainly from an increase of ρ, which overcomes typical limitations of established diagnostic methods as a highly sensitive imaging biomarker for early detection of peripheral nerve lesions. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that MRN accurately identifies asymptomatic mutTTR carriers.
Authors: Xin Jiang; Richard Labaudinière; Joel N Buxbaum; Cecília Monteiro; Marta Novais; Teresa Coelho; Jeffery W Kelly Journal: Proc Natl Acad Sci U S A Date: 2021-03-02 Impact factor: 11.205
Authors: Adriana M Pietsch; Andrea Viehöver; Ricarda Diem; Markus Weiler; Mirjam Korporal-Kuhnke; Brigitte Wildemann; Georges Sam; John M Hayes; Olivia Fösleitner; Johann M E Jende; Sabine Heiland; Martin Bendszus; Jennifer C Hayes Journal: Clin Neuroradiol Date: 2022-10-20 Impact factor: 3.156
Authors: Antonia Carroll; P James Dyck; Mamede de Carvalho; Marina Kennerson; Mary M Reilly; Matthew C Kiernan; Steve Vucic Journal: J Neurol Neurosurg Psychiatry Date: 2022-03-07 Impact factor: 13.654
Authors: Jennifer Kollmer; Ute Hegenbart; Christoph Kimmich; Ernst Hund; Jan C Purrucker; John M Hayes; Stephen I Lentz; Georges Sam; Johann M E Jende; Stefan O Schönland; Martin Bendszus; Sabine Heiland; Markus Weiler Journal: Ann Clin Transl Neurol Date: 2020-04-25 Impact factor: 4.511